Switching HIV Meds for People With M184V Mutation
Part of Immune system & allergy, Infections clinical trials.
This study tests switching your current HIV medicines to a once-daily pill combining doravirine, tenofovir, and lamivudine, specifically for people whose virus has a past M184V mutation but is now well controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older) living with HIV.
- You have been on the same HIV medications for at least 3 months.
- Your HIV viral load has been undetectable (below 50 copies) for at least 6 months.
- You have a specific HIV mutation called M184V/I, but it is no longer found in your current virus testing.
- You cannot have certain other mutations that make your HIV resistant to the study drugs (doravirine or tenofovir).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This study tests how to best dose doravirine for pregnant people with HIV who plan to breastfeed after delivery. The goal is to keep the HIV treatment working safely for both pregnancy and breastfeeding.
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.